Navigation Links
Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
Date:7/17/2009

ization with a strong management team and therapeutic and regulatory expertise, is in the best interest of our stockholders, employees and customers."

In conjunction with the sale of the U.S. assets, the Company also announced the departure of Linda L. Nardone, Ph.D., Encorium's Chief Operating Officer.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i)
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related biology technology :

1. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
2. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
3. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
4. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
5. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
6. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
7. Encorium Reports Third Quarter 2008 Financial Results
8. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
9. Simcere Pharmaceutical Group Notice of Annual General Meeting
10. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
11. Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...wire/ -- Dr. Mate Hidvegi, inventor of Avemar ferm...ase issued on November 17 by Biropharma Kft, discr... self-serving statements about its U.S. competitor...rom his office in Budapest, Hungary: ,, "The B...pply to AveULTRA, www.aveultra.com , is mislead...
(Date:11/19/2009)...ire-FirstCall/ -- Spherix Incorporated (Nasdaq: S...therapy, and a provider of technical and regulator...nology and pharmaceutical companies, today announc...eholders. ,, At the meeting, shareholders of Sp...llowing members to the Board of Directors: ,, ...
(Date:11/19/2009)...- Aegera Therapeutics Inc. announced today the dos...study of AEG35156, a targeted antisense therapeuti...ndications. ,, The study, entitled "An Open-Lab...tor of Apoptosis (XIAP) Antisense AEG35156 Given i...icin in AML Following Failure of a Single Standard...
(Date:11/19/2009)...ed by latest award for revolutionary hearing aid. ...mber 16, 2009 -- Popular Science Magazine has name...om InSound Medical a winner of its coveted Best of...sp;   Chosen from thousands of entr...ing canal for up to four months while providing na...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...illion, Up 46 Percent Over Third Quarter ... of $0.70 per Basic Share, or $0.66 per Diluted Sh...Share, or $1.19 per Diluted ...ed,Therapeutics Corporation (Nasdaq: UTHR ) today...er ended September 30, 2007. Total revenues for t...
...Corporation,(Nasdaq: BPUR ) announced today the p... and warrants. Subject to closing conditions, the,...any 16,850,000 new shares,of Biopure common stock ...ew shares. The price for one share and one warrant...is $1.06. This transaction is expected to,close on...
...ng multiple fluorescent proteins in neurons, neuro...rain and nervous system as never before, rendering... "Brainbow." , The technique is described in the ...ure by a team led by Harvard,s Jean Livet, Joshua ... researchers to tag neurons with roughly 90 distin...
Other Biology Technology:United Therapeutics Reports Third Quarter 2007 Financial Results 2United Therapeutics Reports Third Quarter 2007 Financial Results 3United Therapeutics Reports Third Quarter 2007 Financial Results 4United Therapeutics Reports Third Quarter 2007 Financial Results 5United Therapeutics Reports Third Quarter 2007 Financial Results 6United Therapeutics Reports Third Quarter 2007 Financial Results 7United Therapeutics Reports Third Quarter 2007 Financial Results 8United Therapeutics Reports Third Quarter 2007 Financial Results 9Biopure Announces Pricing of Equity Offering 2Scientists create colorful 'brainbow' images of the nervous system 2
(Date:11/19/2009)...ive survey of genetic diversity in maize, also kno...have developed a gene map that should pave the way...major source of food, fuel, animal feed and fiber ...of gene map known as a haplotype map, charts genet...f 27 inbred lines of maize. The research team, led...
(Date:11/19/2009)...YETTE, Ind. - Purdue University scientists have he...sponsible for cell wall development in maize, an e...to produce the biomass best suited for biofuels pr...as Carpita, a professor of plant cell biology, pub...n the journal Plant Physiology on Thursday (Nov....
(Date:11/19/2009)..., Ill. A new statistical technique developed by r...ientists to scan a genome for specific gene-regula...the relevant transcription factors. The technique ...e genome and the fruit fly genome. , "Our statist... approaches, and is especially useful for investig...
Breaking Biology News(10 mins):Maize cell wall genes identified, giving boost to biofuel research 2Technique finds gene regulatory sites without knowledge of regulators 2REES Announces New San Antonio Office 55668 1REES Announces New San Antonio Office 55668 2Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 1Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 2Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 3Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 4Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 5Varian Medical Systems Adds RapidArc 28R 29 and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clin 55663 1Varian Medical Systems Adds RapidArc 28R 29 and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clin 55663 2Varian Medical Systems Adds RapidArc 28R 29 and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clin 55663 3
...hns Hopkins, senior hospital epidemiologist and fl...ll health care workers as the best means of protec...utbreaks of the viral illness. Studies by other U...nation programs don,t do the job and that each yea...y of them elderly or ill, with weakened immune sys...
...ts have an "ear" for flying in the dark because of...determine their physical environment by listening ...fessor says bats have a "feel" for it, too. , John...ensitive receptors on bats, wings help them mainta...minary findings, presented at the recent Society f...
...searchers at Case Western Reserve University Schoo...d announced that the Food and Drug Administration ...ate the safety of using adult stem cells from bone...of heart disease. , The FDA has approved a Phase I...e. It will involve injecting bone marrow stem cel...
Other Biology News:Johns Hopkins flu expert calls for mandatory vaccination of health care workers 2Johns Hopkins flu expert calls for mandatory vaccination of health care workers 3Bats use touch receptors on wings to fly, catch prey, study finds 2Bats use touch receptors on wings to fly, catch prey, study finds 3Feds give researchers ok for safety test of adult stem cells in patients with heart disease 2
Rabbit Anti-HOXD3 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Goat Anti-Mouse NOV / CCN3 Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human SNAPAP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
HiTrap NHS-activated HP from GE Healthcare, formerly Amersham Biosciences
Biology Products: